Bcl-6 Antibody (Immunohistochemistry)

The Bcl-6 Antibody is an important IHC marker. It helps diagnose and classify
B-cell lymphomas, especially Diffuse Large B-Cell Lymphoma (DLBCL)
and Follicular Lymphoma. In addition, Bcl-6 is a 95 kDa nuclear transcription factor
that regulates B-cell differentiation and germinal center development.

Moreover, Bcl-6 is normally expressed in germinal center B-cells.
As a result, it becomes a reliable marker for follicular-derived lymphomas.
Therefore, it supports accurate distinction between various lymphoma subtypes during pathological evaluation.

🔬 Features and Benefits

• Specific marker for DLBCL and Follicular Lymphoma
• Clear brown nuclear staining in positive cells
• Helps distinguish GCB-type from ABC-type lymphomas
• Compatible with routine IHC protocols
• Stable performance for up to 18 months at 2–8 °C

💡 Diagnostic Applications

• Diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)
• Identification of Follicular and Burkitt Lymphomas
• Differentiation between GCB and ABC lymphoma subtypes
• Research on B-cell differentiation and germinal center biology

🌐 Fardad Azma Rad Co.

Fardad Azma Rad Co., the exclusive representative of
Talent Biomedical in Iran, provides high-quality IHC antibodies, including Bcl-6.
Furthermore, the company focuses on accuracy, global standards, and long-term reliability.
As a result, hematopathology and molecular diagnostic laboratories across Iran benefit from trusted products and professional support.

“Download Brochure”